Литература
1. Gower E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection // J. Hepatol. 2014. Vol. 61, N 1. P. S45-S57.
2. Petruzziello A. et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes // World J. Gastroenterol. 2016. Vol. 22, N 34. P. 7824-7840.
3. Liang TJ. et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C // Ann. Intern. Med. 2000. Vol. 132, N 4. P. 296-305.
4. Shepard C.W. et al. Global epidemiology of hepatitis C virus infection // Lancet Infect. Dis. 2005. Vol. 5, N 9. P 558-567.
5. Coon J.T. et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis // Health Technol. Assess. 2007. Vol. 11, N 34. P. 1-206.
6. Donato F. et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women // Am. J. Epidemiol. 2002. Vol. 155, N 4. P. 323-331.
7. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018 // J. Hepatol. 2018. pii: S0168-8278(18)31968-8.
8. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 3-е изд., испр. и доп. / Н.Д. Ющук и др. М. : ГЭОТАР-Медиа, 2017. 96 с.
9. Van der Meer A.J., Berenguer M. Reversion of disease manifestations after HCV eradication // J. Hepatol. 2016. Vol. 65, N 1. P. S95-S108.
10. Carithers R.L., Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials // Hepatology. 1997. Vol. 26, N 3. P. 83S-88S.
11. Fried M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002. Vol. 347, N 13. P. 975982.
12. Hadziyannis S.J. et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. 2004. Vol. 140, N 5. P. 346355.
13. Manns M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet. 2001. Vol. 358, N 9286. P. 958965.
14. Aghemo A., De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals // Hepatology. 2013. Vol. 58, N 1. P. 428-438.
15. Dore G.J., Matthews G.V., Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals // Curr. Opin. HIV AIDS. 2011. Vol. 6, N 6. P. 508-513.
16. Pawlotsky J.M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens // Gastroenterology. 2016. Vol. 151, N 1. P. 70-86.
17. Инструкция к медицинскому применению препарата симепревир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=17e9ef63-ea93-4c5a-8cc3-0e83bead0b61&t.
18. Инструкция к медицинскому применению препарата нарлапревир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f60ec227-9db2-4c73-9b6a-fd1694cf11d6&t.
19. Инструкция к медицинскому применению препарата асунапревир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=%20a907895c-278f-4851-ba75-e5259ba75359&t.%20.
20. Инструкция к медицинскому применению препарата даклатасвир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=de1dd06c-e526-4e30-b8d8-794c2ade02f9&t.
21. Инструкция к медицинскому применению препарата софос-бувир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=354729ed-4d65-4c32-9af1-4799a7104d2c&t .
22. Инструкция к медицинскому применению препарата дасабувир; омбитасвир + паритапревир + ритонавир. (дата обращения: 01.02.2018)
URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6c1d682d-e3be-426a-906d-685921f037af&t .
23. Vermehren J. et al. Retreatment of patients who failed DAA-combi-nation therapies: real-world experience from a large hepatitis C resistance database // J. Hepatol. 2016. Vol. 64, N 2. P. S188.
24. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice // J. Hepatol. 2016. Vol. 64, N 2.P. 486-504.
25. Rong L. et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus // Sci. Transl. Med. 2010. Vol. 2, N 30. P 30ra32.
26. Martell M. et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution // J. Virol. 1992. Vol. 66, N 5. P 3225-3229.
27. Fourati S., Pawlotsky J.M. Virologic tools for HCV drug resistance testing // Viruses. 2015. Vol. 7, N 12. P 6346-6359.
28. Dietz J. et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients // PLoS One. 2015. Vol. 10, N 8. Article ID e0134395.
29. Kuntzen T. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients // Hepatology. 2008. Vol. 48, N 6. P 1769-1778.
30. Chen Z. et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data // Sci. Rep. 2016. Vol. 6. Article ID 20310.
31. Wyles D.L. Resistance to DAAs: when to look and when it matters // Curr. HIV/AIDS Rep. 2017. Vol. 14, N 6. P 229-237.
32. Kliemann D.A. et al. Genetic barrier to direct acting antivirals in HCV sequences deposited in the European Databank // PLoS One. 2016. Vol. 11, N 8. Article ID e0159924.
33. Le Pogam S. et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients // J. Antimicrob. Chemother. 2008. Vol. 61, N 6. P. 1205-1216.
34. European Association for The Study of The Liver et al. EASL recommendations on treatment of hepatitis C 2016 // J. Hepatol. 2017. Vol. 66, N 1. P. 153.
35. Pawlotsky J.M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens // Gastroenterology. 2016. Vol. 151, N 1. P. 70-86.
36. Highlights of prescribing information. (дата обращения: 01.02.2018)
URL: http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
37. Calleja J.L. et al. NS5A resistance: clinical implications and treatment possibilities // AIDS Rev. 2016. Vol. 18, N 1. P 15-22.
38. Dvory-Sobol H. et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir // J. Hepatol. 2015. Vol. 62, suppl. 2. P. S221.
39. Lahser F. et al. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection // Hepatology. 2016. Vol. 63, N 1, suppl. P 32A.
40. Sullivan J.C. et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials // Clin. Infect. Dis. 2013. Vol. 57, N 2. P. 221-229.
References
1. Gower E., Estes C, Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61 (1): S 45-57.
https://www.sciencedirect.com/science/article/pii/S0168827814005261
doi: 10.1016/j.jhep.2014.07.027
2. Petruzziello A., Marigliano S., Loquercio G., et al. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22 (34): 7824-40.
https://pubmed.ncbi.nlm.nih.gov/27678366-global-epidemiology-of-hepatitis-c-virus-infection-an-up-date-of-the-distribution-and-circulation-of-hepatitis-c-virus-genotypes/
doi: 10.3748/wjg.v22.i34.7824
3. Liang T.J., Rehermann B., Seeff L.B., et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132 (4): 296-305.
4. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection // The Lancet infectious diseases. Lancet Infect Dis. 2005; 5 (9): 558-67.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(05)70216-4/fulltext
doi: 10.1016/S1473-3099(05)70216-4
5. Thompson Coon J., Rogers G., Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007; 11 (34): 1-206.
6. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002; 155 (4): 323-31.
7. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018. pii: S0168-8278(18)31968-8.
https://pubmed.ncbi.nlm.nih.gov/29650333-easl-recommendations-on-treatment-of-hepatitis-c-2018/
doi: 10.1016/j.jhep.2018.03.026
8. Jushhuk N.D., et al. Recommendation of diagnostic and therapy of adult patients with Hepatitis C virus. Moscow: GEOTAR-Media, 2017: 96 p. (in Russian)
9. Van der Meer A.J., Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016; 65 (1): S95-108.
https://pubmed.ncbi.nlm.nih.gov/27641991-reversion-of-disease-manifestations-after-hcv-eradication/
doi: 10.1016/j.jhep.2016.07.039
10. Carithers R.L., Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997; 26 (3 Suppl 1): 83S-8S.
https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.510260715
doi: 10.1002/hep.510260715
11. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347 (13): 975-82.
https://pubmed.ncbi.nlm.nih.gov/12324553-peginterferon-alfa-2a-plus-ribavirin-for-chronic-hepatitis-c-virus-infection/
doi: 10.1056/NEJMoa020047
12. Hadziyannis S.J., SetteH. Jr, Morgan T.R., et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140 (5): 346-55.
13. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 (9286): 958-65.
14. Aghemo A., De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013; 58 (1): 428-38.
https://pubmed.ncbi.nlm.nih.gov/23467911-new-horizons-in-hepatitis-c-antiviral-therapy-with-direct-acting-antivirals/
doi: 10.1002/hep.26371
15. Dore G.J., Matthews G.V., Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 2011; 6 (6): 50813.
https://pubmed.ncbi.nlm.nih.gov/21897228-future-of-hepatitis-c-therapy-development-of-direct-acting-antivirals/
doi: 10.1097/COH.0b013e32834b87f8
16. Pawlotsky J.M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016; 151 (1): 70-86.
https://pubmed.ncbi.nlm.nih.gov/27080301-hepatitis-c-virus-resistance-to-direct-acting-antiviral-drugs-in-interferon-free-regimens/
doi: 10.1053/j.gastro.2016.04.003
17. Instruction to simeprevir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=17e9ef63-ea93-4c5a-8cc3-0e83bead0b61&t. (date of access February 1, 2018) (in Russian)
18. Instruction to narlaprevir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f60ec227-9db2-4c73-9b6a-fd1694cf11d6&t. (date of access February 1, 2018) (in Russian)
19. Instruction to asunaprevir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=%20a907895c-278f-4851-ba75-e5259ba75359&t.%20. (date of access February 1, 2018) (in Russian)
20. Instruction to daclatasvir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=de1dd06c-e526-4e30-b8d8-794c2ade02f9&t (date of access February 1, 2018) (in Russian)
21. Instruction to sofosbuvir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=354729ed-4d65-4c32-9af1-4799a7104d2c&t. (date of access February 1, 2018) (in Russian)
22. Instruction to dasabuvir; ombitasvir+ paritaprevir+ ritonavir. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6c1d682d-e3be-426a-906d-685921f037af&t. (date of access February 1, 2018) (in Russian)
23. Vermehren J., Susser S., Dietz. J., et al. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol. 2016. 64 (2): S188.
24. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016; 64 (2): 486-504.
https://www.google.com/search?q=Sarrazin+C.+The+importance+of+resistance+to+direct+antiviral+drugs+in+HCV+infection+in+clinical+practice.&oq=Sarrazin+C.+The+importance+of+resistance+to+direct+antiviral+drugs+in+HCV+infection+in+clinical+practice.&aqs=chrome..69i57.575j0j7&sourceid=chrome&ie=UTF-8
doi: 10.1016/j.jhep.2015.09.011
25. Rong L., Dahari H., Ribeiro R.M., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010; 2 (30): 30ra32.
https://pubmed.ncbi.nlm.nih.gov/20445200-rapid-emergence-of-protease-inhibitor-resistance-in-hepatitis-c-virus/
doi: 10.1126/scitranslmed.3000544
26. Martell M., Esteban J.I., Quer J., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66 (5): 3225-9.
27. Fourati S., Pawlotsky J. M. Virologic tools for HCV drug resistance testing. Viruses. 2015; 7 (12): 6346-59.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/
doi: 10.3390/v7122941
28. Dietz J., Susser S., Berkowski C., et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One. 2015; 10 (8): e0134395.
https://pubmed.ncbi.nlm.nih.gov/26317755-consideration-of-viral-resistance-for-optimization-of-direct-antiviral-therapy-of-hepatitis-c-virus-genotype-1-infected-patients/
doi: 10.1371/journal.pone.0134395
29. Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008; 48 (6): 1769-78.
https://pubmed.ncbi.nlm.nih.gov/19026009-naturally-occurring-dominant-resistance-mutations-to-hepatitis-c-virus-protease-and-polymerase-inhibitors-in-treatment-naive-patients/
doi: 10.1002/hep.22549
30. Chen Z., Li H., Ren H., et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the Gen-Bank HCV genome data. Sci Rep. 2016; 6: 20310.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740856/
doi: 10.1038/srep20310
31. Wyles D.L. Resistance to DAAs: when to look and when it matters. Curr HIV/AIDS Rep. 2017; 14 (6): 229-37.
https://pubmed.ncbi.nlm.nih.gov/29116550-resistance-to-daas-when-to-look-and-when-it-matters/
doi: 10.1007/s11904-017-0369-5
32. Kliemann D.A., Tovo C.V., Gorini da Veiga A.B., et al. Genetic barrier to direct acting antivirals in HCV sequences deposited in the European Databank. PLoS One. 2016; 11 (8): e0159924.
https://pubmed.ncbi.nlm.nih.gov/27504952-genetic-barrier-to-direct-acting-antivirals-in-hcv-sequences-deposited-in-the-european-databank/
doi: 10.1371/journal.pone.0159924
33. Le Pogam S., Seshaadri A., Kosaka A., et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother. 2008; 61 (6): 1205-16.
https://pubmed.ncbi.nlm.nih.gov/18343801-existence-of-hepatitis-c-virus-ns5b-variants-naturally-resistant-to-non-nucleoside-but-not-to-nucleoside-polymerase-inhibitors-among-untreated-patients/
doi: 10.1093/jac/dkn085
34. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017; 66 (1): 153-94.
https://pubmed.ncbi.nlm.nih.gov/27667367-easl-recommendations-on-treatment-of-hepatitis-c-2016/
doi: 10.1016/j.jhep.2016.09.001
35. Pawlotsky J.M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016; 151 (1): 70-86.
https://www.gastrojournal.org/article/S0016-5085(16)30055-5/fulltext
doi: 10.1053/j.gastro.2016.04.003
36. Highlights of prescribing information. URL: http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
37. Calleja J.L., Llerena S., Perello C., et al. NS5A resistance: clinical implications and treatment possibilities. AIDS Rev. 2016; 18 (1): 15-22.
38. Dvory-Sobol H., Wyles D., Ouyang W. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015; 62 (2): S221.
39. Lahser F., Galloway A., Hwang P., et al. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants. (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection. Hepatology. 2016; 64 (1 Suppl): 32A.
40. Sullivan J.C., De Meyer S., Bartels D.J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013; 57 (2): 221-9.
https://academic.oup.com/cid/article/57/2/221/313856
doi: 10.1093/cid/cit226